Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer
Author:
Affiliation:
1. Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States
2. Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01491
Reference41 articles.
1. Concepts in sumoylation: a decade on
2. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways
3. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition
4. Structural Basis for E2-Mediated SUMO Conjugation Revealed by a Complex between Ubiquitin-Conjugating Enzyme Ubc9 and RanGAP1
5. Protein Modification by SUMO
Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase;Nature Communications;2024-01-31
2. Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells;Journal of Biomedical Science;2024-01-27
3. A comprehensive review of discovery and development of drugs discovered from 2020–2022;Saudi Pharmaceutical Journal;2024-01
4. Paralogue-Specific Roles of SUMO1 and SUMO2/3 in Protein Quality Control and Associated Diseases;Cells;2023-12-20
5. PTEN‐mediated dephosphorylation of 53BP1 confers cellular resistance to DNA damage in cancer cells;Molecular Oncology;2023-12-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3